Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neurofibromatosis 1 × cabozantinib × 1 year × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 43 Carcinoma, Hepatocellular 12 Neoplasm Metastasis 7 Prostatic Neoplasms 6 Neoplasms 6 Kidney Neoplasms 6 Sarcoma 5 Osteosarcoma 5 Clear-cell metastatic renal cell carcinoma 5 Sarcoma, Ewing 4 Neuroendocrine Tumors 4 Colorectal Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Carcinoma 4 Brain Neoplasms 4 Urinary Bladder Neoplasms 3 Urethral Neoplasms 3 Thyroid Neoplasms 3 Ovarian Neoplasms 3 Melanoma 3 Endometrial Neoplasms 3 Carcinoma, Transitional Cell 3 Carcinoma, Medullary 3 Urogenital Neoplasms 2 Ureteral Neoplasms 2 Triple Negative Breast Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Small Cell Lung Carcinoma 2 Recurrence 2 Penile Neoplasms 2

Interventions

AZD 6244 11 trametinib 2 Lasers, Solid-State 2 Deoxycholic Acid 2 thymoglobulin 1 talimogene laherparepvec 1 omipalisib 1 mirdametinib 1 fludarabine 1 dabrafenib 1 cabozantinib 1 binimetinib 1 Waiting Lists 1 Vincristine 1 Specimen Handling 1 Rituximab 1 Polidocanol 1 Photochemotherapy 1 Melphalan 1 Magnetic Resonance Spectroscopy 1 Lovastatin 1 Liquid Biopsy 1 Levetiracetam 1 Lasers 1 Inhalation 1 Dosage Forms 1 Cyclophosphamide 1 Curcumin 1 Carboplatin 1 Busulfan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06502171 2026-03-12

NF113

University of Alabama at Birmingham

Phase 1 Not yet recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon ⚡